Home » STUDIES IN US POSITIVE ON ASTRAZENECA ASTHMA TREATMENT
STUDIES IN US POSITIVE ON ASTRAZENECA ASTHMA TREATMENT
US studies comparing AstraZeneca's Symbicort asthma treatment with alternatives have reported favourable results for the UK- and Sweden-based drug major. The trials evaluated the drug's performance against a conventional therapy based on fixed-dose medicines, administered with a separate reliever treatment. The combined budesonide and formoterol inhaled drug reportedly reduced severe asthma symptoms by 45% among the 2,760 mild to moderate asthma sufferers surveyed. AstraZeneca has already developed its Pulmicort asthma spray for European markets.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct